【肥胖药物生产商Rivus据悉考虑最快今年上市】金十数据10月7日讯，据知情人士透露，专注于肥胖治疗的药物开发商Rivus Pharmaceuticals Inc.正考虑最早于2024年在美国进行首次公开募股(IPO)。知情人士说，该公司正在与银行就上市事宜进行合作。其中一位知情人士说，Rivus的目标可能是筹集2.5亿美元以上的资金。RA Capital Management是Rivus的投资者之一。机构数据显示，9月份是自2021年以来美国上市数量最多的一个月，因此IPO将寻求利用生物制药行业的势头。同样在研发治疗肥胖症药物的BioAge Labs Inc.上个月扩大了IPO规模，筹资2.28亿美元，自9月26日上市以来已上涨25%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.